Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -111.81% | -135.21% | -79.06% | -156.24% | -80.07% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,095.19% | 113.75% | 163.97% | 36.73% | -113.74% |
| Change in Net Operating Assets | -336.16% | 1,290.10% | -51.84% | -289.19% | -16.08% |
| Cash from Operations | -127.58% | -113.90% | -101.10% | -199.67% | -178.53% |
| Capital Expenditure | 100.60% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 217.31% | 37.82% | -- | -- | -- |
| Cash from Investing | 216.82% | 37.50% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 1,850.71% | -1,850.71% | -- | -- |
| Cash from Financing | 20,924.41% | -99.88% | 91.15% | -- | -100.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.03% | -398.29% | -995.41% | 3,577.70% | -142.71% |
